Fenugreek is a bitter food legume sold as a culinary spice and as standardised seed extracts. Its best-supported effects are metabolic: lower blood sugar and blood fats, a slightly lower upper blood pressure number, and a smaller waist. In women, menopausal and period-pain symptoms improve. Its most advertised use, raising testosterone, is the weakest part of the record. Effects are largest when starting values are already disturbed. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–85 mg/dL | Primary efficacy target |
| HbA1c (glycated haemoglobin) | 4.8–5.3% | Confirms sustained glycaemic change |
| Fasting insulin | 2–5 µIU/mL | Detects insulin-sensitivity change the glucose value hides |
| Triglycerides | < 80 mg/dL | The lipid fraction fenugreek moves most |
| LDL cholesterol | < 80 mg/dL | Tracks the bile-acid-binding effect |
| HDL cholesterol | > 55 mg/dL (men), > 65 mg/dL (women) | The one lipid fraction expected to rise |
| ALT and AST (transaminases) | < 20 U/L (women), < 25 U/L (men) | Safety check for herb–drug liver injury |
| Serum potassium | 4.0–4.5 mmol/L | Screens the reported low-potassium signal |
| Total and free testosterone | Age- and sex-specific reference; track change from own baseline | Tests the hormonal claim in the individual |
| Oestradiol | No established target for supplemented adults; track change from own baseline | Detects the phytoestrogenic shift trials report |
| Thyroid-stimulating hormone | 0.5–2.0 mIU/L | Catches fibre-mediated levothyroxine malabsorption |
| Blood pressure (home cuff) | < 120/80 mmHg | Tracks the systolic effect |
Cadence: Baseline panel before the first dose; capillary glucose several times weekly for the first four weeks alongside glucose-lowering medication; repeat panel at 12 weeks; then every 6–12 months while use continues. Alongside a narrow-margin drug cleared by the liver, a transaminase check joins the 12-week panel.